MetaCap

Processa Pharmaceuticals (PCSA) vs Scienture (SCNX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Processa Pharmaceuticals is the larger company by market cap ($4.4 million vs $4.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PCSA+9.86%SCNX-44.85%
+41%-4%-49%
Oct 7, 20261 yearNov 20, 2026
PCSA+2.63%SCNX-39.42%
+30%-6%-43%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PCSA versus SCNX key metrics
MetricPCSASCNX
Share price$1.56$2.28
Market cap$4.37M$4.07M
1-day change-7.69%-6.45%
EPS (TTM)$-68.29$-51.70
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$431.61K
Revenue growth (YoY)—+215.87%
Net income (latest FY)$-13.56M$-41.51M
Gross margin—76.80%
Operating margin—-9867.92%
Net margin—-9618.03%
52-week high$8.88$18.75
52-week low$1.04$2.00
Distance from 52-week high-82.43%-87.85%
Analyst consensus—buy
Avg. price target upside—+1546.25%
Average volume79.50K156.51K
Shares outstanding2.80M1.79M
Employees124
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Processa Pharmaceuticals

PCSA stock →

Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

About Scienture

SCNX stock →

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

PCSA vs SCNX FAQ

Which is bigger, Processa Pharmaceuticals or Scienture?

Processa Pharmaceuticals (PCSA) is larger, with a market capitalization of $4.37M compared with $4.07M for Scienture (SCNX).

Are Processa Pharmaceuticals and Scienture in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons